Thousands of clinical trial participants and patients have reported significant improvement in their vision by two rows on the visual acuity eye chart, and 100% increase in contrast sensitivity function, on average.
Figure 1: Change in Visual Acuity during NeuroVision™ of three amblyopic patients and one control patient
Figure 2: Change in visual acuity during NeuroVision treatment of two treatment groups and one control group
Polat et al. studied 54 adult amblyopic patients who were randomized to amblyopia NVT treatment or a placebo vision-training program. Pre treatment visual acuity in both study groups were 0.42 logMAR, and this improved by 2.5 lines to 20/30 in the NVT treatment group, with no improvement in the control group. The Contrast Sensitivity Function (CSF) improved to within the normal range. These improvements in acuity and CSF were sustained after 12 months1.
Figure 3: UACSF improvement in study group subjects maintained after 12 months (n-20 eyes)
Figure 4: UAVA improvement in study group subjects maintained after 12 months (n-20 eyes)
Tan et al. reported mean improvement of 2.8 logMar lines in distance unaided visual acuity (UAVA) for 55 low myopes after completion of the NVT training. The improvements were shown to be retained for at least 12 months5.
At 2007 Asia-ARVO, Tan et al. reported mean distance UAVA improvement was 2.4 ETDRS lines(from 0.32 to 0.08 logMar) in distance unaided (UAVA) for 22 post-refractive surgery patients after completion of the NVT training. Mean distance unaided CSF improved at all spatial frequencies to within the normal range6. Similar result reported by Durrie et al in 2007 on the efficacy of NV on low myopes.
| Group A | Group B | |
| Baseline unaided VA (logMar) Mean (SD) Median (range) |
0.43 (0.15) 0.40 (0.20 - 0.80) |
0.34 (0.10) 0.32 (0.20 - 0.62) |
| End of treatment VA (logMar) Mean (SD) Median (range) |
0.25 (0.17) 0.24 (-0.30 - 0.66) |
0.31 (0.17) 0.28 (-0.12 - 0.70) |
| Improvement of VA (logMar) Mean (SD) Median (range) |
0.183 (0.155) 0.18 (-0.28 - 0.60) |
0.03 (0.144) 0.04 (-0.30 - 0.34) |
Table 1: Summary of baseline VA, end of treatment VA and improvement of VA
| Group A | Group B | Statistical Significance (p) | Odds Ratio | 95% confidence Interval | |
| Average Improvement in UAVA | 0.183 logMar | 0.030 logMar | |||
| % of subjects who improved 2 Lines or above in Both Eyes | 31.3% | 5.9% | p=0.034 Fisher's Extract Test |
7.304 | 0.908 to 58.771 |
| % of subjects who improved 2 Lines or above in at least One Eye | 64.2% | 11.8% | p<0.0005 Chi-square Test |
13.438 | 2.830 to 63.796 |
Table 2: Summary of Statistical Analysis
Tan et al. conducted a randomized controlled trial evaluating the efficacy of NVT in low myopia. The interim results presented by Tan et al, at Asia ARVO 2008 confirmed that statistically significant difference in unaided visual acuity between the masked treatment groups and suggested on completion of the NVT was likely to provide the definitive evidence of efficacy and safety of NVT treatment in improving visual acuity and contrast sensitivity function in adult low myopes10.
Figure 5: Change in unaided visual acuity during NeuroVision treatment
Figure 6: Change in unaided contrast sensitivity during the NeuroVision treatment.Lim et al. reported a single case of NVT for the treatment low myopic regression five years after myopic LASIK. The patient improved 2.8 lines in the right eye and 1.6 lines in the left eye following NVT2.
Figure 7: Unaided VA is retained for 24 months after the end of the NeuroVision treatment
Figure 8: Unaided contrast sensitivity is retained for 24 months after the end of the NeuroVision treatmentSiow et al. reported 2 years follow-up results of visual acuity and contrast sensitivity enhancement in commercial patients with low myopia using NVT training program. Mean logMAR UAVA improved from 0.404 to 0.110 at the end of treatment approximately 3 rows of improvement in acuity. 74% of this improvement was maintained after 24 months.
Mean baseline UCSF at 1.5, 3, 6, 12, 18 cpd was: 39, 41, 23, 7, 2 improving to: 117, 145, 148, 61, 18. 76% of this improvement was maintained for 24 months. The sesults suggest that NVC treatment improves UAVA and UCSF in low myopes. This improvement is retained for at least 24 months after treatment9.
| n=20 | Treatment Group |
| Mean PHVA, PLVA, MHVA before treatment | 0.06, 0.21, 0.19 (±0.02, ±0.02, ±0.02) |
| Mean PHVA, PLVA, MHVA after treatment | -0.05, 0.14, 0.08 (±0.02, ±0.02, ±0.02) |
| PHVA, PLVA, MHVA improvement post treatment | 0.11, 0.07, 0.11 (±0.03, ±0.02, ±0.02) |
| Mean PHVA, PLVA, MHVA 3 mth after treatment | -0.05, 0.19, 0.09 (±0.03, ±0.05, ±0.04) |
| Mean cycloplegic spherical equivalence refraction before treatment | -2.70D (±0.49) |
| Mean cycloplegic spherical equivalence refraction after treatment | -2.16D (±0.58) |
| Percentage with better than 0.00 logMAR VA (6/6) post treatment | 70% |
Table 3: Summary of visual functions of subjects had undergone NeuroVision treatment
Figure 9: Summary of contrast sensitivity functions of subjects had undergone NeuroVision treatmentNg et al. reported mean habitual VA improved from 0.06 (0 to 0.28) to -0.05 (-0.22 to 0) logMAR units in a group of 11 young adults at 2007 Asia-ARVO. 70% of the eyes achieved VA better than 6/6 at the end of NeuroVision treatment. Statistical significant improvements were found in contrast sensitivity after the end of treatment. The results demonstrate super vision is achieved after the Neurovision treatment7.
| n=98 | Treatment Group | Control Group |
| All patients after "NeuroLASIK" Unaided Visual Acuity improvement Contrast Sensitivity improvement |
0.8 Snellen Lines 79% |
0.28 Snellen Lines 52% |
| Patients with vision worse than 20/20 after "NeuroLASIK" Unaided Visual Acuity improvement Contrast Sensitivity improvement |
1.56 Snellen Lines 90% |
0.34 Snellen Lines 47% |
Table 3: Comparison of Unaided VA and Contrast Sensitivity improvement between "NeuroLASIK" treatment group and control group
Durrie et al. conducted a prospective, randomized, multicenter placebo controlled study comparing visual cortex training after LASIK ("NeuroLASIK") to sham treatment (video game) following LASIK in 98 eyes. Researchers found 0.8 Snellen lines of UAVA and 79% improvement in contrast sensitivity in the treatment group relative to a 0.28 line improvement and 52% improvement in CSF in the control group. Patients who were worse than 20/20 after LASIK improved 1.56 Snellen lines of UAVA and 90% improvement in CSF with NVT relative to the 0.34 lines and 47% CSF improvement in the control group. The results suggested that patients who had worse vision improved more and that perhaps there is a cortical limit to how much a patient can improve11.
References
- Improving vision in adult amblyopia by perceptual learning
PNAS 2004 - NeuroVision Treatment for Low Myopia Following LASIK Regression
Journal of Refractive Surgery 2006 - Donald Tan, MD, on NeuroVision™, a Non-optical Approach to Correcting the Effects of Refractive Error
Refractive Eyecare 2006 - Efficacy of neural vision therapy to enhance contrast sensitivity function and visual acuity in low myopia
J Cataract Refract Surg 2008 - Improving CSF in Subjects with Low Degrees of Myopia using Neural Vision CorrectionÔ (NVCÔ) Technology
Donald Tan poster presented in 2005 ARVO - The Alternative Approach to Visual Blur: NeuroVision Treatment (NVCÔ) for Myopia, Post-Refractive Surgery and Presbyopia
Donald Tan, Chua Wei Han, Allan Fong poster presented in 2007 Asia AVRO - Cortical enhancement of Habitual VA of subjects using Neural Vision Correction Technology
Chris NG, Wilfred TANG, Donald TAN, Nir ELLENBOGAN poster presented in 2007 Asia AVRO - Efficacy of NeuroVision Technology (NVC) in Enhancing Unaided Vision in Early Presbyopes and Low Myopes
Erin D. Stahl, MD, Daniel S. Durrie, MD poster presented in 2007 AAO - 2 Years Follow-Up Results of Visual Acuity and Contrast Sensitivity Enhancement in Patients with Low Myopia using NeuroVision's Neural Vision Correction (NVC) Technology
Ka-Lin Siow, Donald T.H. Tan poster presented in IMC 2008 - A Randomised Controlled Trial Evaluating the Efficacy of Neurovision's Neural Vision Correction Technology in Enhancing Unaided Visual Acuity in Adults with Low Myopia
Muhammad Nazarul, Allan Fong, Donald Tan presented in 2008 ARVO - Computer-Based Primary Visual Cortex Training Combined with LASIK for Treatment of Low Myopia
Erin D. Stahl, MD, Daniel S. Durrie, MD presented in 2009 ASCRS